N-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)-ethanamine | 83195-54-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)-ethanamine
• 英文别名: methyl 4-[2-[(3-trifluoromethyl-β-hydroxyphenethyl)amino]propyl]phenoxyacetate；N-[2-(4-Carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl) ethanamine；methyl 2-[4-[2-[[2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]propyl]phenoxy]acetate
• CAS: 83195-54-4
• 化学式: C₂₁H₂₄F₃NO₄
• 分子量: 411.421
• InChiKey: BLODOBGCBZUDTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  475.1±45.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)-ethanamine 在 sodium borohydrid 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-[2-(4-(2-Hydroxyethoxy)-phenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)ethanamine
  参考文献：
  名称：

  Secondary amines and compositions for treatment of hypoglycaemia or

  摘要：

  化合物的结构式（I）：##STR1##或其盐；其中R.sup.1为氢，甲基或乙基；R.sup.2为氢，甲基或乙基；R.sup.3为氢，氟，氯，溴或三氟甲基；R.sup.4和R.sup.5中的每一个为氢，氟，氯，溴，C.sub.1-6烷基或C.sub.1-6烷氧基；n为1或2；X为C.sub.1-12直链或支链烷基，及其盐，具有抗肥胖、降糖、抗炎和抑制血小板聚集作用。

  公开号：

  US04382958A1
• 作为产物：
  描述：

  2-氨基-1-[3-(三氟甲基)苯基]乙醇 、 4-(2-氧代丙基)苯氧乙酸甲酯 在 正己烷 作用下， 生成 N-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)-ethanamine
  参考文献：
  名称：

  Ethanamine derivatives their preparation and use in pharmaceutical

  摘要：

  式（II）的化合物：##STR1## 其中R.sub.1是氢、氟、氯或溴原子或羟基、羟甲基、甲基、甲氧基、氨基、甲酰胺基、乙酰胺基、甲磺酰胺基、硝基、苄氧基、甲磺酰甲基、脲基、三氟甲基或对甲氧基苄氨基基团；R.sub.2是氢、氟、氯或溴原子或羟基；R.sub.3是氢、氯或溴原子或羟基；R.sub.4是氢原子或甲基基团；R.sub.5是氢原子或甲基基团；R.sub.6是氢、氟或氯原子或甲基、甲氧基或羟基团；X是氧原子或键；Y是最多6个碳原子的烷基基团或键；Z是最多10个碳原子的烷基、烯基或炔基团，已被发现具有抗肥胖和/或抗高血糖活性。

  公开号：

  US04338333A1

文献信息

• Tertiary amines
  申请人：Beecham Group plc

  公开号：US04803293A1

  公开（公告）日：1989-02-07

  Compounds of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, in which R.sup.1 is hydrogen, halogen, or trifluoromethyl, R.sup.2 is hydrogen or halogen, R.sup.3 is hydroxyl, C.sub.1-6 alkoxy or ##STR2## where R.sup.8 and R.sup.9 are each hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen or C.sub.1-6 alkyl; R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyl optionally substituted by hydroxy; cyano, C.sub.1-6 alkenyl or C.sub.1-6 alkynyl optionally substituted by carboxy or esters and amides thereof, phenyl, C.sub.1-6 alkyl phenyl or a group ##STR3## wherein R.sup.12 and R.sup.13 are each hydrogen or C.sub.1-6 alkyl or together, along with the nitrogen to which they are attached, form a 5- or 6-membered ring and m is 1 or 2; R.sup.6 is hydrogen or methyl: R.sup.7 is --O(CH.sub.2).sub.a CO.sub.2 H, --O(CH.sub.2).sub.b M, --CO.sub.2 H; or amide thereof in which a is an integer from 1 to 6, b is an integer from 2 to 7, and M is hydroxy, C.sub.1-6 alkoxy or ##STR4## in which R.sup.10 and R.sup.11 are each hydrogen or C.sub.1-6 alkyl or ##STR5## together form a five or six membered ring; and n is 1 or 2; with the proviso that when n is 2 and R.sup.1, R.sup.2, R.sup.4 and R.sup.6 are each hydrogen and R.sup.3 is hydroxyl, R.sup.5 is not hydroxymethyl or 1-hydroxy ethyl when R.sup.7 is CONH.sub.2 ; processes for preparing such compounds and their use in medicine.

  化学式(I)的化合物：##STR1##或其药学上可接受的盐，其中R.sup.1是氢，卤素或三氟甲基，R.sup.2是氢或卤素，R.sup.3是羟基，C.sub.1-6烷氧基或##STR2##其中R.sup.8和R.sup.9分别是氢或C.sub.1-6烷基; R.sup.4是氢或C.sub.1-6烷基; R.sup.5是氢，C.sub.1-6烷基，C.sub.1-6烷基可选择地被羟基取代;氰基，C.sub.1-6烯基或C.sub.1-6炔基，可选择地被羧基或其酯和酰胺取代，苯基，C.sub.1-6烷基苯基或##STR3##其中R.sup.12和R.sup.13分别是氢或C.sub.1-6烷基，或连同它们所连接的氮一起形成5-或6-成员环，m为1或2; R.sup.6是氢或甲基：R.sup.7是--O(CH.sub.2).sub.a CO.sub.2 H，--O(CH.sub.2).sub.b M，--CO.sub.2 H;或其酰胺，其中a是1到6的整数，b是2到7的整数，M是羟基，C.sub.1-6烷氧基或##STR4##其中R.sup.10和R.sup.11分别是氢或C.sub.1-6烷基或##STR5##共同形成五元或六元环; n为1或2；但当n为2且R.sup.1，R.sup.2，R.sup.4和R.sup.6分别为氢，而R.sup.3为羟基时，当R.sup.7为CONH.sub.2时，R.sup.5不是羟甲基或1-羟乙基；制备这种化合物的方法以及它们在医学上的用途。
• Secondary amines
  申请人：BEECHAM GROUP PLC

  公开号：EP0052963A1

  公开（公告）日：1982-06-02

  A compound of formula (I). or a salt thereof; wherein R1 is hydrogen, methyl or ethyl; R2 is hydrogen, methyl or ethyl; R3 is hydrogen, fluorine, chlorine, bromine or trifluoromethyl; each of R4 and R5 is hydrogen, fluorine, chlorine, bromine, C1-6 alkyl or C1-6 alkoxy; n is 1 or 2; and X is C1-12 straight or branched alkylene, and salts thereof, are anti-obesity, hypoglycaemic, anti-inflammatory and platelet aggregation inhibiting agents.

  一种式(I)化合物 或其盐，其中 R1 为氢、甲基或乙基；R2 为氢、甲基或乙基；R3 为氢、氟、氯、溴或三氟甲基；R4 和 R5 各为氢、氟、氯、溴、C1-6 烷基或 C1-6 烷氧基；n 为 1 或 2；X 为 C1-12 直链或支链亚烷基，及其盐是抗肥胖、降血糖、抗炎和血小板聚集抑制剂。
• Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
  申请人：BEECHAM GROUP PLC

  公开号：EP0070133A2

  公开（公告）日：1983-01-19

  Compounds of formula (I): and salts and in vivo hydrolysable acyl derivatives thereof, wherein R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is phenyl unsubstituted or substituted with one or two of the following:- fluorine, chlorine, bromine, trifluoromethyl, C1-6 straight or branched chain alkyl or C1-6 straight or branched chain alkoxy; or is benzofuran-2-yl; R5 is a hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; R4 is moiety wherein X is C2-10 alkylene which may be straight or branched provided that the oxygen and nitrogen are separated by at least two carbon atoms, A is hydrogen; C1-6 straight or branched alkyl or benzyl optionally substituted with halogen, lower alkyl or lower alkoxy. R6 is hydrogen; C1-6 straight or branched alkyl; C1-6 straight or branched alkylsulphonyl R7 is C1-6 straight or branched alkyl; C1-6 straight or branched alkoxy; amino, mono- or di- (C1-6 straight or branched alkyl) amino; or is a 5,6 or 7 membered cyclic amine optionally containing a second hetero atom selected from oxygen, nitrogen and sulphur, and n is 1 or 2 have anti-obesity and anti-hyperglycaemic activity.

  式(I)化合物： 及其盐类和体内可水解酰基衍生物，其中 R1 是氢或甲基 R2 是氢或甲基 R3 是未取代的苯基或被下列一个或两个取代的苯基 氟、氯、溴、三氟甲基、C1-6 直链或支链烷基或 C1-6 直链或支链烷氧基；或苯并呋喃-2-基； R5 是氢、卤素、羟基、低级烷基或低级烷氧基； R4 是分子 其中 X 为 C2-10 亚烷基，可以是直链或支链亚烷基，条件是氧和氮至少相隔两个碳原子、 A 是氢；C1-6 直链或支链烷基或苄基，可选择被卤素、低级烷基或低级烷氧基取代。 R6 是氢；C1-6 直链或支链烷基；C1-6 直链或支链烷基磺酰基 R7 是 C1-6 直链或支链烷基；C1-6 直链或支链烷氧基；氨基，单-或二-（C1-6 直链或支链烷基）氨基；或 是 5、6 或 7 个成员的环胺，可选择含有选自氧、氮和硫的第二个杂原子、 且 n 为 1 或 2 的化合物具有抗肥胖和抗高血糖活性。
• Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals
  申请人：BEECHAM GROUP PLC

  公开号：EP0085514A2

  公开（公告）日：1983-08-10

  A pharmaceutieally acceptable composition comprising a β-agonist and a β-antagonist selected from propranolol, sotalol, atenolol, metoprolot, and salts or esters thereof, useful in the treatment of obese humans or animals. The composition is particularly useful in the treatment of an obese human, or animal suffering from a heart complaint. In which case the treatment with a β-agonist alone may unacceptably aggravate the heart complaint.

  一种药学上可接受的组合物，包含一种β-受体激动剂和一种选自普萘洛尔、索他洛尔、阿替洛尔、美托洛尔及其盐或酯类的β-受体激动剂，可用于治疗肥胖的人或动物。该组合物尤其适用于治疗肥胖的人或患有心脏疾病的动物。在这种情况下，单独使用β-受体激动剂可能会使心脏疾病恶化到不可接受的程度。
• Novel Morpholines
  申请人：BEECHAM GROUP PLC

  公开号：EP0170135A1

  公开（公告）日：1986-02-05

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, in which R' is hydrogen, halogen or trifluoromethyl; R2 is hydrogen or halogen; R3 is hydrogen or methyl; R4 is -O(CH2)a CO2H or an ester or amide derivative thereof, O(CH2)bM or -CO2H or an ester or amide derivative thereof wherein a is an integer from 1 to 6, b is an integer from 2 to 7, and M is hydroxy, C1-6 alkoxy or wherein R6 and R7 are each hydrogen or C1-6 alkyl or together form a five or six membered ring; R5 is C1-6 alkyl; C1-6 alkyl substituted by carboxy or esters and amides thereof; or phenyl optionally substituted by C1-6 alkyl, halogen, alkoxy or trifluoromethyl; R8 is hydrogen or C1-6 alkyl or R8 together with R5 form a carbocyclic ring; and n is 1 or 2. Processes for preparing these compounds and their use in therapy is also described.

  式 (I) 的化合物 或其药学上可接受的盐，其中 R' 是氢、卤素或三氟甲基； R2 是氢或卤素 R3 是氢或甲基 R4 是-O(CH2)a CO2H 或酯或酰胺衍生物 O(CH2)bM或-CO2H或其酯或酰胺衍生物 其中 a 是 1 至 6 的整数、 b 是 2 至 7 的整数，以及 M 是羟基、C1-6 烷氧基或 其中 R6 和 R7 分别为氢或 C1-6 烷基或 共同形成一个五或六个成员的环； R5 是 C1-6 烷基；被羧基或其酯和酰胺取代的 C1-6 烷基；或任选被 C1-6 烷基、卤素、烷氧基或三氟甲基取代的苯基； R8 是氢或 C1-6 烷基，或 R8 与 R5 一起形成碳环；以及 n 为 1 或 2。 还描述了制备这些化合物的工艺及其在治疗中的用途。